149 COMMONWEALTH DRIVE, MENLO PARK, CA
Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Other Events
Stockholders Approve Amendment to 2024 Incentive Award Plan
FDA Approves Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Provides Update on Patent Dispute with Teva Pharmaceuticals
Overall Survival Primary Endpoint Met in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
S-8 POS